On Friday, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) opened higher 1.12% from the last session, before settling in for the closing price of $8.95. Price fluctuations for SNDX have ranged from $8.58 to $25.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1801.91% over the past five years. Company’s average yearly earnings per share was noted -1.92% at the time writing. With a float of $82.52 million, this company’s outstanding shares have now reached $86.05 million.
Let’s look at the performance matrix of the company that is accounted for 270 employees. In terms of profitability, gross margin is -3.44%, operating margin of -786.59%, and the pretax margin is -757.52%.
Syndax Pharmaceuticals Inc (SNDX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Syndax Pharmaceuticals Inc is 2.20%, while institutional ownership is 115.42%. The most recent insider transaction that took place on Mar 04 ’25, was worth 117,564. In this transaction Chief Executive Officer of this company sold 7,814 shares at a rate of $15.05, taking the stock ownership to the 300,121 shares. Before that another transaction happened on Mar 04 ’25, when Company’s Officer proposed sale 13,888 for $15.48, making the entire transaction worth $214,986.
Syndax Pharmaceuticals Inc (SNDX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -1.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.49% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Check out the current performance indicators for Syndax Pharmaceuticals Inc (SNDX). In the past quarter, the stock posted a quick ratio of 5.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.87, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -2.69 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) saw its 5-day average volume 2.81 million, a positive change from its year-to-date volume of 2.24 million. As of the previous 9 days, the stock’s Stochastic %D was 5.97%. Additionally, its Average True Range was 0.97.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 5.62%, which indicates a significant decrease from 8.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 119.53% in the past 14 days, which was higher than the 73.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.21, while its 200-day Moving Average is $15.85. Nevertheless, the first resistance level for the watch stands at $9.20 in the near term. At $9.35, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.55. If the price goes on to break the first support level at $8.85, it is likely to go to the next support level at $8.65. The third support level lies at $8.50 if the price breaches the second support level.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
There are currently 86,047K shares outstanding in the company with a market cap of 778.73 million. Presently, the company’s annual sales total 23,680 K according to its annual income of -318,760 K. Last quarter, the company’s sales amounted to 20,040 K and its income totaled -84,850 K.
